Long-term observation of familial hypereosinophilia and its effects
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
This study looks at a hereditary condition called familial hypereosinophilia to see how it affects people over time and to learn more about its causes and markers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 1 Year to 100 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00091871 on ClinicalTrials.gov |
What this trial studies
This study investigates familial hypereosinophilia (FE), a hereditary form of hypereosinophilic syndrome, by enrolling approximately 50 individuals from a previously studied family. Participants will undergo yearly clinical evaluations, including medical history, physical examinations, and various tests such as bloodwork and echocardiograms. The study aims to understand the natural history, genetic causes, and disease markers associated with FE, while also collecting biological specimens for further research. Although the study does not focus on treatment, appropriate medical care will be provided for those who need it.
Who should consider this trial
Good fit: Ideal candidates include genetically related individuals aged 1-100 from families previously identified with familial hypereosinophilia.
Not a fit: Patients without a genetic link to a family with familial hypereosinophilia or those with conditions that pose unacceptable risks will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of familial hypereosinophilia, potentially improving patient outcomes.
How similar studies have performed: While this study focuses on familial hypereosinophilia, similar studies on hypereosinophilic syndrome have shown promise in understanding the condition's mechanisms.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 1-100 years of age * Genetically related member of a previously identified family with FE * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Any condition that the investigator feels put the subject at unacceptable risk for participation in the study * Pregnancy (in family members who do not have eosinophilia)
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Amy D Klion, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Thomas W Brown, R.N.
- Email: browntw@mail.nih.gov
- Phone: (301) 402-7823
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.